Your browser is no longer supported. Please, upgrade your browser.
PRFX [NASD]
PainReform Ltd.
Index- P/E- EPS (ttm)- Insider Own23.10% Shs Outstand9.05M Perf Week-9.77%
Market Cap33.46M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float7.74M Perf Month-6.42%
Income- PEG- EPS next Q-0.51 Inst Own44.90% Short Float1.26% Perf Quarter-6.10%
Sales- P/S- EPS this Y-362.10% Inst Trans- Short Ratio0.06 Perf Half Y-37.33%
Book/sh2.25 P/B1.23 EPS next Y26.50% ROA- Target Price- Perf Year-
Cash/sh1.61 P/C1.72 EPS next 5Y- ROE- 52W Range2.18 - 7.85 Perf YTD-38.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.71% Beta-
Dividend %- Quick Ratio28.80 Sales past 5Y- Gross Margin- 52W Low27.06% ATR0.73
Employees1 Current Ratio28.80 Sales Q/Q- Oper. Margin- RSI (14)45.42 Volatility19.44% 26.75%
OptionableNo Debt/Eq0.00 EPS Q/Q-117.20% Profit Margin- Rel Volume0.91 Prev Close2.83
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.55M Price2.77
Recom2.00 SMA20-9.19% SMA50-6.86% SMA200-32.11% Volume1,404,632 Change-2.12%
Jun-15-21 12:46PM  
May-24-21 06:35AM  
May-13-21 08:15AM  
Mar-18-21 09:15AM  
Mar-11-21 10:43AM  
Mar-08-21 09:00AM  
Jan-07-21 08:30AM  
Jan-06-21 08:30AM  
Jan-04-21 08:30AM  
Nov-23-20 08:30AM  
Nov-12-20 09:00AM  
Nov-05-20 08:30AM  
Oct-19-20 09:00AM  
Sep-29-20 07:30AM  
Sep-09-20 02:15PM  
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.